Acumen Pharmaceuticals, Inc. — Form 10-Q
Filed October 26, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 3/100
What the filing says
CEO Daniel O'Connell and CFO Matthew Zuga certified the Q3 2026 10-Q filing (period ended September 30, 2026, filed October 26, 2026) as compliant with SOX requirements. Both officers attested to the accuracy of financial statements and effectiveness of disclosure controls and internal controls over financial reporting, with no material weaknesses or fraud disclosures noted.
Why this rating
Routine boilerplate certification exhibits; no factual disclosure of business operations, transactions, or financial changes. Non-material standard filing.
See more from October 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.